Foley is proud to be a sponsor of the ACC’s 2009 Annual Meeting. This years meeting is taking place at the Hynes Convention Center in Boston, MA on October 18-21, 2009.
We also are pleased to announce that two of the 2009 Annual Meeting panels will feature Foley attorneys.
- Jon Dudas, Foley IP Litigation Partner and former Under Secretary of Commerce for Intellectual Property and Director of the USPTO, will speak on the “Meet the USPTO Brass” panel, along with Lynne Beresford, Commissioner for Trademarks at the USPTO, and Robert Budens, President of the Patent Office Professional Association
Tuesday, October 20, 2009 • 9:00 a.m. – 10:30 a.m.
- Jon Dudas and Catherine Sun, Foley Shanghai Office Managing Partner and Asia Practice Chair, will speak on the “Orienting East: IP in China” panel. Joining them will be Michelle Deng, Patent Counsel with Genzyme Corporation, and Bonita Bell, Vice President and Deputy General Counsel of Terex Corporation
Wednesday, October 21, 2009 • 9:00 a.m. – 10:30 a.m.
For further information or to register, please visit the ACC Web site.
Related Insights
June 6, 2025
Energy Current
House Bill 3809 Adds Obligations to Battery Energy Storage Lessees in Texas
On May 29, 2025, House Bill No. 3809 was signed into law by Texas Governor Greg Abbott. Born out of a crop of bills regulating renewable…
June 23, 2025
Events
Third Annual Transaction Solutions Symposium
Foley & Lardner is sponsoring the Third Annual Transaction Solutions Symposium — a premier conference focused on de-risking strategies that enhance deal execution and business outcomes. Rishi Sodhi will be speaking as part of the Tax Liability Insurance: Current Trends, Controversies and Claims panel.
June 5, 2025
Health Care Law Today
GLP-1 Compounded Medications Targeted by Connecticut Attorney General
On May 21, 2025, the Connecticut Office of the Attorney General released a statement and sent letters to Connecticut weight loss clinics, med spas, medical practices and other businesses regarding allegedly or potentially unfair and deceptive conduct relating to compounded GLP-1 medications.